Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

BACKGROUND AND PURPOSE: Impaired ambulation is a prominent disabling symptom of multiple sclerosis and can lead to reduced quality of life. Whether natalizumab, a monoclonal antibody shown to reduce disease activity in relapsing−remitting multiple sclerosis, could impact ambulation performance was e...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Neurol
Autori principali: Voloshyna, N, Havrdová, E, Hutchinson, M, Nehrych, T, You, X, Belachew, S, Hotermans, C, Paes, D
Natura: Artigo
Lingua:Inglês
Pubblicazione: BlackWell Publishing Ltd 2015
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4365753/
https://ncbi.nlm.nih.gov/pubmed/25511792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ene.12618
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi